Upadacitinib for Treatment of Granulomatous Cheilitis-Reference-Cited by-同舟云学术

Upadacitinib for Treatment of Granulomatous Cheilitis

Published:2024-07-31 Issue: Volume: Page:
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

De Greef Axel¹²,Peeters Caroline¹,Dewit Olivier³⁴,de Montjoye Laurence¹²,Baeck Marie¹²

Affiliation:

1. Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium

2. Institute of Experimental and Clinical Research (IREC), Pneumology, ENT and Dermatology Pole (LUNS), Université catholique de Louvain (UCLouvain), Brussels, Belgium

3. Department of Gastroenterology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium

4. Institute of Experimental and Clinical Research (IREC), Pole of Research in Hepato-Gastroenterology (GAEN), Université catholique de Louvain (UCLouvain), Brussels, Belgium

Abstract

This case series examines the effectiveness of the Janus kinase inhibitor upadacitinib for the treatment of granulomatous cheilitis.

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2821679/jamadermatology_de_greef_2024_ld_240012_1722027526.11519.pdf

Reference6 articles.

1. Oro-facial granulomatosis—a clinical and pathological analysis.;Wiesenfeld;Q J Med,1985

2. Orofacial granulomatosis.;Miest;Clin Dermatol,2016

3. Granulomatous cheilitis preceding gastrointestinal manifestations of Crohn’s disease.;Eubanks;Am J Dermatopathol,2023

4. Low response of granulomatous cheilitis to currently established treatments.;Kreuter;J Eur Acad Dermatol Venereol,2021

5. Janus kinase inhibitors in dermatology, part II: a comprehensive review.;Chapman;J Am Acad Dermatol,2022